Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

• Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy

• Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):

‣ Positive capillary-lymphovascular space involvement and one of the following:

• Deep third penetration

∙ Middle third penetration, clinical tumor \>= 2 cm

∙ Superficial third penetration, clinical tumor \>= 5 cm

⁃ Negative capillary-lymphatic space involvement

• Middle or deep third penetration, clinical tumor \>= 4 cm

• Absolute neutrophil count (ANC) \>= 1,500/mcl

• Platelets \>= 100,000/mcl

• Creatinine =\< upper limit of normal (ULN) or calculated creatinine clearance \>= 60 mL/min

• Bilirubin =\< 1.5 x normal

• Alkaline phosphate =\< 3 x normal

• Serum glutamic oxaloacetic transaminase (SGOT) =\< 3 x normal

• Gynecologic Oncology Group (GOG) performance status 0, 1, 2

• Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery

• Patients who have met the pre-entry requirements

• Patients must have signed an approved informed consent and authorization permitting release of personal health information